

# E Dianne Pulte

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8728681/e-dianne-pulte-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65  
papers

2,631  
citations

23  
h-index

51  
g-index

66  
ext. papers

2,988  
ext. citations

4.5  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
65	Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. <i>Oncologist</i> , <b>2010</b> , 15, 994-1001	5.7	452
64	Recent major improvement in long-term survival of younger patients with multiple myeloma. <i>Blood</i> , <b>2008</b> , 111, 2521-6	2.2	433
63	Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. <i>Blood</i> , <b>2009</b> , 113, 1408-11	2.2	161
62	Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. <i>Oncologist</i> , <b>2011</b> , 16, 1600-3	5.7	122
61	Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. <i>Blood</i> , <b>2008</b> , 111, 4916-21	2.2	111
60	Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. <i>Haematologica</i> , <b>2009</b> , 94, 270-5	6.6	107
59	Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1301-9	9.7	99
58	Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. <i>Blood</i> , <b>2008</b> , 111, 2977-83	2.2	87
57	Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. <i>Haematologica</i> , <b>2008</b> , 93, 594-600	6.6	85
56	Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. <i>Haematologica</i> , <b>2013</b> , 98, 222-9	6.6	72
55	Survival of adults with acute lymphoblastic leukemia in Germany and the United States. <i>PLoS ONE</i> , <b>2014</b> , 9, e85554	3.7	67
54	Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1083-9	1.9	65
53	Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 469-76		64
52	Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 189-196	4.5	59
51	CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 367-72	2	54
50	Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. <i>Cancer</i> , <b>2009</b> , 115, 4973-9	6.4	49
49	Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. <i>Haematologica</i> , <b>2008</b> , 93, 1544-9	6.6	36

48	Changes in the survival of older patients with hematologic malignancies in the early 21st century. <i>Cancer</i> , <b>2016</b> , 122, 2031-40	6.4	35
47	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 28	22.4	32
46	Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. <i>Oncologist</i> , <b>2011</b> , 16, 663-71	5.7	30
45	FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. <i>Oncologist</i> , <b>2018</b> , 23, 1366-1371	5.7	28
44	Subsite-specific colorectal cancer risk in the colorectal endoscopy era. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 75, 621-30	5.2	28
43	Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 540-5	3.8	24
42	Social disparities in survival after diagnosis with colorectal cancer: Contribution of race and insurance status. <i>Cancer Epidemiology</i> , <b>2017</b> , 48, 41-47	2.8	22
41	Disparities in Colon Cancer Survival by Insurance Type: A Population-Based Analysis. <i>Diseases of the Colon and Rectum</i> , <b>2018</b> , 61, 538-546	3.1	22
40	Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 70	22.4	20
39	Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma. <i>Oncologist</i> , <b>2015</b> , 20, 554-61	5.7	19
38	Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 979-85	1.9	18
37	Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012. <i>Cancer Epidemiology</i> , <b>2012</b> , 36, e19-25	2.8	17
36	Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 851-7	4.5	16
35	Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. <i>Oncologist</i> , <b>2009</b> , 14, 806-13	5.7	16
34	Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 179-86	1.9	15
33	FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a Mutation. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3515-3521	12.9	15
32	Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 56	7	14
31	Age disparities in survival from lymphoma and myeloma: a comparison between US and England. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 824-31	4.5	14

30	Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 1289-96	7.5	14
29	Case series of octogenarians with sickle cell disease. <i>Blood</i> , <b>2016</b> , 128, 2367-2369	2.2	13
28	Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 3227-3239 <sup>12</sup>	7.5	12
27	Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. <i>Blood Advances</i> , <b>2018</b> , 2, 116-119	7.8	11
26	Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. <i>Cancer</i> , <b>2019</b> , 125, 2656-2665	6.4	10
25	Survival of patients with gastric lymphoma in Germany and in the United States. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1485-91	4	10
24	Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 century. <i>Haematologica</i> , <b>2017</b> , 102, e229-e232	6.6	7
23	Survival disparities by age and country of diagnosis for patients with acute leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2787-92	1.9	7
22	Survival for patients with rare haematologic malignancies: Changes in the early 21st century. <i>European Journal of Cancer</i> , <b>2017</b> , 84, 81-87	7.5	7
21	Outcome disparities by insurance type for patients with acute myeloblastic leukemia. <i>Leukemia Research</i> , <b>2017</b> , 56, 75-81	2.7	5
20	Comparison of Emergency Department Wait Times in Adults with Sickle Cell Disease Versus Other Painful Etiologies. <i>Hemoglobin</i> , <b>2016</b> , 40, 330-334	0.6	5
19	Population-Level Differences in Rectal Cancer Survival in Uninsured Patients Are Partially Explained by Differences in Treatment. <i>Oncologist</i> , <b>2017</b> , 22, 351-358	5.7	4
18	Long-term survival in chronic myelocytic leukemia after a first primary malignancy. <i>Leukemia Research</i> , <b>2009</b> , 33, 1604-8	2.7	4
17	Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin. <i>Hemoglobin</i> , <b>2014</b> , 38, 385-9	0.6	3
16	Population-Level Survival for Patients With Chronic Myeloid Leukemia: Higher Survival in Sweden Than Internationally. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 695-696	2.2	2
15	Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 324-332	7.5	2
14	Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101548	2.2	2
13	Erythropoietin Levels in Patients with Sickle Cell Disease Not in Vaso-Occlusive Crisis. <i>Blood</i> , <b>2012</b> , 120, 3242-3242	2.2	1

12	Red Cell Alloimmunization in Sickle Cell Disease: Benefit of Extended Crossmatching in Adults. <i>Blood</i> , <b>2012</b> , 120, 4761-4761	2.2	1
11	Influence of insurance type on survival in patients with acute myeloblastic leukemia.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17612-e17612	2.2	1
10	U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. <i>Oncologist</i> , <b>2019</b> , 24, e188-e195	5.7	1
9	In Reply. <i>Oncologist</i> , <b>2015</b> , 20, 1224	5.7	
8	Ongoing Strong Improvement in Treatment Outcomes for Patients Diagnosed with Non-Hodgkin Lymphoma from the 1990s to the Early 21st Century.. <i>Blood</i> , <b>2007</b> , 110, 3314-3314	2.2	
7	Characteristics of "Older Old" Patients with Sickle Cell Anemia Who Survived for More Than 80 Years. <i>Blood</i> , <b>2015</b> , 126, 4599-4599	2.2	
6	Population Level Survival for Patients with Multiple Myeloma: Variation and Growing Disparity for Patients of Minority Race or Ethnicity. <i>Blood</i> , <b>2011</b> , 118, 3126-3126	2.2	
5	Changes in Survival in Acute Myeloblastic Leukemia by Racial and Ethnic Group: Greater Improvement for Non-Hispanic Whites and Increase in the Disparity for Minority Patients in the Early 21st Century. <i>Blood</i> , <b>2011</b> , 118, 844-844	2.2	
4	Population Level Survival of Patients with Chronic Myeloid Leukemia in Germany in the Early 21st Century. <i>Blood</i> , <b>2012</b> , 120, 759-759	2.2	
3	An International Comparison Of Survival Disparities In Patients With Lymphoma and Myeloma. <i>Blood</i> , <b>2013</b> , 122, 2925-2925	2.2	
2	Survival Disparities By Insurance Type For Patients With Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 1737-1737	2.2	
1	Incidence and survival estimates for patients with myelodysplastic syndrome in the early 21st century: no evidence of improvement over time.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-6	1.9	